Over the past two decades, research has shown that overexpression and hypersecretion of CTSD have increased in many types of cancer, including ovarian cancer and breast cancer, endometrial cancer, lung cancer, and cancer glioma, melanoma, and prostate cancer [36–41]. Here, CTSD is linked to lung carcinoma.